About Beth Spiegelman
Form D filings for Kyverna Therapeutics in 2023 list Beth Spiegelman as director.
Beth Spiegelman first appears on SEC filings in 2023.
Experience
This experience comes from SEC filings. The years are when the filings name Beth Spiegelman in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Beth Spiegelman works with at each company, as listed on that company's latest Form D.
Kyverna Therapeutics, Inc. · Form D, Nov 7, 2023
BK
Brian Kotzin
Director
IC
Ian Clark
Director
RJ
Ryan Jones
Chief Financial Officer
KW
Karen Walker
Executive officer
PM
Peter Maag
Executive officer and director
JC
James Chung
Executive officer
DS
Dan Spiegelman
Director
FC
Fred Cohen
Director
SL
Steve Liapis
Director
DB
Dominic Borie
Executive officer